Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Longitudinal immune dynamics associated with chronic lymphocytic leukemia development in mice with 13q14 deletion and modulation by early BTK inhibition

View Full Paper
Ask AI
Bookmark
Share

Authors

ICIñaki Salvador CorresHIHristo IlievDMDaniel Medina

Discussion

Loading...

Member takes

Overview

Longitudinal immune profiling reveals BTK inhibition reduces CLL incidence and modulates T-cell dynamics in mice.

Key Points

  • To define immune mechanisms driving Chronic Lymphocytic Leukemia and assess the effects of acalabrutinib on disease development.
  • Two cohorts of mice established: MDR-deleted and wild-type with blood sampling over time.
  • One cohort randomized to receive acalabrutinib or vehicle prior to CLL onset.
  • Immune dynamics assessed by spectral flow cytometry and analyzed using GBTM.
  • MDR-deleted mice showed shorter survival than wild-type, with increased CLL incidence.
  • Acalabrutinib treatment reduced CLL incidence and burden compared to vehicle.
  • Changes in T-cell subsets and dynamics identified before CLL onset.

Cite This Study

Corres et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8aahttps://doi.org/10.1182/blood-2025-5656
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy.2024
  2. 2Systematic molecular profiling to identify determinants of response to ibrutinib2025
  3. 3Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators2025
  4. 4Abstract 7533: The protease MALT1 is required for chronic lymphocytic leukemia genesis in Eμ-TCL1 mice2026
  5. 5Mutational profile of previously treated chronic lymphocytic leukemia patients progressing on acalabrutinib or ibrutinib2024 · 48 citations